These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16518915)

  • 21. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
    Bleser S
    Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New capacities of the probiotic therapy in the treatment of the irritated bowels syndrome].
    Tkachenko EI; Uspenskiĭ IuP; Balukova EV; Baryshnikova NV
    Eksp Klin Gastroenterol; 2006; (3):26-30. PubMed ID: 17203839
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey.
    Rangan V; Ballou S; Shin A; Camilleri M; ; Lembo A
    Gastroenterology; 2020 Feb; 158(3):786-788.e1. PubMed ID: 31711922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Heat-killed
    Seong G; Lee S; Min YW; Jang YS; Kim HS; Kim EJ; Park SY; Kim CH; Chang DK
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33572194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study.
    Yoon JY; Cha JM; Oh JK; Tan PL; Kim SH; Kwak MS; Jeon JW; Shin HP
    Dig Dis Sci; 2018 Oct; 63(10):2754-2764. PubMed ID: 29876777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that amitriptyline may be effective in treating diarrhea-predominant irritable bowel syndrome.
    Lundberg GD
    Medscape J Med; 2008 Jun; 10(6):132. PubMed ID: 18679541
    [No Abstract]   [Full Text] [Related]  

  • 27. Probiotics and digestive disease.
    Mullin GE
    Nutr Clin Pract; 2012 Apr; 27(2):300-2. PubMed ID: 22367887
    [No Abstract]   [Full Text] [Related]  

  • 28. Questions about mesalazine and the irritable bowel syndrome.
    Farup PG
    Aliment Pharmacol Ther; 2011 Oct; 34(8):1036-7; author reply 1037-8. PubMed ID: 21933210
    [No Abstract]   [Full Text] [Related]  

  • 29. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study.
    O'Sullivan MA; O'Morain CA
    Dig Liver Dis; 2000 May; 32(4):294-301. PubMed ID: 11515626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
    Kane JS; Ford AC
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. End points in irritable bowel syndrome.
    Mangel AW; Fehnel SE
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract]   [Full Text] [Related]  

  • 34. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea.
    Brigidi P; Vitali B; Swennen E; Bazzocchi G; Matteuzzi D
    Res Microbiol; 2001 Oct; 152(8):735-41. PubMed ID: 11686387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.
    Lan L; Chen YL; Zhang H; Jia BL; Chu YJ; Wang J; Tang SX; Xia GD
    World J Gastroenterol; 2014 Aug; 20(32):11422-8. PubMed ID: 25170231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacteriotherapy using fecal flora: toying with human motions.
    Borody TJ; Warren EF; Leis SM; Surace R; Ashman O; Siarakas S
    J Clin Gastroenterol; 2004 Jul; 38(6):475-83. PubMed ID: 15220681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the efficacy of probiotics to treat diarrhea.
    Wang F; Zhao T; Wang W; Dai Q; Ma X
    Medicine (Baltimore); 2022 Sep; 101(38):e30880. PubMed ID: 36197181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of probiotics use in the pediatric population.
    May ME; So TY
    Clin Pediatr (Phila); 2014 Nov; 53(13):1231-8. PubMed ID: 24419268
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.